volume 19, issue 2, P351-365 2005
DOI: 10.1016/j.idc.2005.03.005
View full text
|
|
Share
Khalil G. Ghanem, Julie A. Giles, Jonathan M. Zenilman

Abstract: The worldwide incidence of fluoroquinolone-resistant Neisseria gonorrhoeae has increased dramatically in the last few years. Single doses of fluoroquinolones can no longer be used to treat N gonorrhoeae infections acquired in the Far East, parts of the Middle East, the Pacific Islands, and parts of Western Europe and the United States. Although California and Hawaii account for most of the current United States cases, the increased incidence of FQR in some high-risk groups independent of geography heralds an i…

expand abstract